---
title: "\u00bfCu\u00e1nto costar\u00e1 su operaci\u00f3n en honorarios?"
description: "Honorarios en operaciones de EE. UU., no precios de compra: asesor\u00eda, legal, salida a bolsa, colocaci\u00f3n y Chapter 11."
site: Deal Cost Index
content_updated: 2026-10-29
license: CC BY 4.0
html: https://dealcostindex.com/index-es.html
---
Honorarios en operaciones de EE. UU.

# ¿Cuánto costará su operación en honorarios?

El Deal Cost Index mide lo que las empresas pagan a bancos de inversión, abogados, auditores, colocadores y proveedores de salas de datos para completar una operación. Los precios de compra, los múltiplos de valoración y el coste de la financiación quedan fuera de este sitio.

Introduzca su operación para proyectar los honorarios de asesoría, legales, contables, de due diligence y de sala de datos. Cada partida se proyecta a partir de registros públicos, encuestas publicadas o tarifas de proveedores, y enlaza con su fuente.

Construido a partir de

660

documentos de fusión y ofertas públicas

502

folletos de salida a bolsa

52,571

rondas privadas (Form D)

47

procedimientos del Chapter 11

132

valores de encuestas publicadas

Registros de la SEC y de los tribunales de quiebras de EE. UU., 2023–2026.

Honorarios proyectados

$4.4M–$10.7M — Venta (lado vendedor) · $250M

- M&A advisor fees 93%

- Deal counsel 5%

- Sell-side quality of earnings 2%

- Virtual data room <1%

Suma de las 4 partidas marcadas como incluidas, proyectada a partir de registros públicos, encuestas publicadas y tarifas de los proveedores. Las partidas en gris se muestran como referencia y no se suman.

Una proyección, no un presupuesto. Este rango se deriva de información pública sobre otras operaciones. Los honorarios de su operación dependerán de sus hechos, de las firmas que contrate y de lo que negocie. Nada de lo aquí expuesto es asesoramiento financiero, legal, fiscal o de inversión. [Términos y aviso legal](https://dealcostindex.com/terms.html)

continues to $25M →

$0$9.16M

| Partida | Mitad central y mediana | Rango |
|---|---|---|
| M&A advisor fees (all target-side advisors)Filed 58 registrosTotal target-side advisor fees as a share of deal value in 58 disclosed deals ($125M–$500M): median 2.60%, middle half 1.73%–3.66%. Public-target deals; private deals of this size usually pay at least as much. |  | $4.32M–$9.16Mmediana $6.5M |
| Fairness opinion fee (part of the advisor fee)Filed 45 registros · Solo como referenciaPortion payable on delivery of the opinion, from the same filings. Usually credited against the success fee. |  | $1M–$1.75Mmediana $1M |
| Lehman / Double Lehman formulaFormula · Solo como referencia5-4-3-2-1 and 10-8-6-4-2 schedules applied to $250M. Shown for reference; this is not an observed fee. |  | $2.6M–$5.2Mmediana $3.9M |
| Monthly retainerSurvey · Solo como referencia$5,000–$10K a month is the most common retainer, over 6 months; most advisors credit it against the success fee. [Firmex 2025](https://4804905.fs1.hubspotusercontent-na1.net/hubfs/4804905/Firmex-MAFeeGuide-Global-25.pdf) |  | $30K–$60Kmediana $45K |
| Deal counselSurveyExternal legal spend per M&A deal reported by US private equity firms (average $353K, range $50K–$1M, 2020 data). Large-firm partners in New York averaged $1,972/hour in H1 2025. [Apperio 2020](https://www.persuit.com/learn/typical-manda-deals-cost-us-private-equity-353k-in-legal-spend-and-other-outside-counsel-statistics-from-us-based-pe-firms) [Wolters Kluwer ELM Solutions via B 2025](https://www.nasdaq.com/press-release/wolters-kluwer-study-sets-stage-2026-sharp-contrasts-regional-law-firm-rates-and) |  | $50K–$1Mmediana $353K |
| Sell-side quality of earningsSurveyPublished price ranges for a >$150M deal: boutique providers $25K–$50K, buy-side QoE $150K–$400K, sell-side priced 10–30% higher. [BD Emerson 2026](https://www.bdemerson.com/article/quality-of-earnings-report-cost) [Bedrock Quality of Earnings 2026](https://www.bedrockqoe.com/insights/quality-of-earnings-report-cost) |  | $25K–$520Kmediana $114K |
| Virtual data roomList price 8 registrosMiddle half of list-price totals from 8 vendors whose published plans cover 20 GB and 2 admins for 6 months, billed monthly where offered. Plans are priced for the months billed, not the months used. [How data room totals are calculated](https://dealcostindex.com/vdr.html#billing-basis) |  | $2,499–$18Kmediana $3,764 |
| R&W insuranceSurvey · Solo como referenciaLimit 10% of EV ($25M) × rate on line 2–3.5% (Q4 2025 average 3.23%), plus underwriting fee and up to 6% surplus lines tax. [Gallagher 2025](https://www.ajg.com/-/media/files/gallagher/us/news-and-insights/2025/transactional-risk-2025-review-and-2026-outlook.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) [Vanbridge 2024](https://www.vanbridge.com/wp-content/uploads/2024/02/2024-Vanbridge-Reps-and-Warranties-Reference-Guide.pdf) Typically paid by the buyer; sometimes split. |  | $535K–$978Kmediana $850K |
| Escrow held back (not a fee)Survey · Solo como referenciaCash withheld from proceeds, typically released after ~12 months: median 2.8% of deal value with R&W insurance, 10% without. [DealLawyers.com 2026](https://www.deallawyers.com/blog/2026/04/study-private-target-deal-terms-10.html) [SRS Acquiom 2025](https://www.srsacquiom.com/our-insights/ma-deals/) Typically paid by the buyer; sometimes split. |  | $7M–$25Mmediana $7M |
| Total |  | $4.4M–$10.7MSuma de las medianas $6.97M |

La base de cada partida, las notas que la acompañan y las tablas de operaciones comparables permanecen en inglés: citan y parafrasean los documentos de los que proceden, y en este sitio las citas no se traducen. La versión inglesa de esta página es la que prevalece.

## Public-company deals used ($125M–$500M)

Each fee is taken from the filing; hover over a fee to see the sentence it comes from. Deal values marked “computed” are the cash price per share multiplied by shares outstanding.

| Target | Deal value | Advisor | Fee | % of value | Source |
|---|---|---|---|---|---|
| Greenbacker Renewable Energy | $375M — stated | Wells Fargo Securities | $7M | 1.87% | [DEFM14A Oct 2026](https://www.sec.gov/Archives/edgar/data/1563922/000175392626001969/g085989_defm14a.htm) |
| Nathans Famous, Inc. | $418M — computed | Jefferies | $9.6M | 2.30% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/69733/000110465926110393/tm267612-2_defm14a.htm) |
| Luxfer Holdings PLC | $465M — computed | Deutsche Bank | $8M | 1.72% | [DEFM14A Sep 2026](https://www.sec.gov/Archives/edgar/data/1096056/000207709626000260/ea0303080-02.htm) |
| AstroNova, Inc. — acquired by Arcline | $225M — computed | Rockefeller | $4.2M | 1.87% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/8146/000119312526326441/d140981ddefm14a.htm) |
| Simulations Plus, Inc. | $375M — stated | Morgan Stanley | $11M | 2.93% | [DEFM14A Jul 2026](https://www.sec.gov/Archives/edgar/data/1023459/000102345926000051/defm14a.htm) |
| Open Lending Corp — acquired by Anv | $236M — computed | FT | $8.7M | 3.68% | [SC 14D9 Jun 2026](https://www.sec.gov/Archives/edgar/data/1806201/000119312526286952/d140679dsc14d9.htm) |
| Cross Country Healthcare Inc. | $428M — computed | BofA Securities | $6.12M | 1.43% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/1141103/000114036126025249/ny20073866x2_defm14a.htm) |
| XOMA Royalty Corp | $489M — computed | Leerink Partners | $18.4M | 3.76% | [DEFM14A Jun 2026](https://www.sec.gov/Archives/edgar/data/791908/000119312526266069/d137792ddefm14a.htm) |
| Sun Country Airlines Holdings, Inc. — acquired by Allegiant | $218M — computed | Goldman Sachs | $22.6M | 10.36% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1743907/000114036126012383/ny20068391x1_defm14a.htm) |
| Calavo Growers, Inc. — acquired by Mission Produce | $486M — stated | Jefferies | $12.5M | 2.57% | [DEFM14A Mar 2026](https://www.sec.gov/Archives/edgar/data/1133470/000119312526117814/d15959ddefm14a.htm) |
| Diamond Hill Investment Group, Inc. — acquired by First Eagle | $430M — computed | Broadhaven | $7M | 1.63% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/909108/000114036126002681/ny20061565x2_defm14a.htm) |
| Crawford United Corporation — acquired by Spx | $300M — stated | Lake StreetStout | $2.4M | 0.80% | [DEFM14A Jan 2026](https://www.sec.gov/Archives/edgar/data/47307/000143774926000391/crawa20260103_defm14a.htm) |
| TrueCar, Inc. | $227M — computed | Morgan Stanley | $12.5M | 5.51% | [DEFM14A Nov 2025](https://www.sec.gov/Archives/edgar/data/1327318/000110465925115451/tm2528639-6_defm14a.htm) |
| WideOpenWest, Inc. — acquired by DigitalBridge and Crestview | $290M — stated | Centerview Partners | $19.4M | 6.69% | [DEFM14A Oct 2025](https://www.sec.gov/Archives/edgar/data/1701051/000110465925102255/tm2523589-7_defm14a.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525225023/d846289dsc14d9a.htm) |
| Potbelly Corporation — acquired by RaceTrac | $409M — computed | Piper Sandler | $6.9M | 1.69% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1195734/000119312525213634/d936677dsc14d9.htm) |
| scPharmaceuticals Inc. | $285M — computed | Leerink Partners | $8.8M | 3.09% | [SC 14D9 Sep 2025](https://www.sec.gov/Archives/edgar/data/1604950/000119312525198383/d152074dsc14d9.htm) |
| Y-mAbs Therapeutics, Inc. — acquired by Serb | $354M — computed | Centerview Partners | $9.1M | 2.57% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1722964/000110465925079582/tm2523645-2_sc14d9.htm) |
| DallasNews Corp | $150M — computed | J.P. Morgan | $5M | 3.34% | [DEFM14A Aug 2025](https://www.sec.gov/Archives/edgar/data/1413898/000119312525181885/d24897ddefm14a.htm) |
| iTeos Therapeutics, Inc. | $385M — computed | TD Cowen | $9.5M | 2.47% | [SC 14D9 Aug 2025](https://www.sec.gov/Archives/edgar/data/1808865/000119312525170952/d854787dsc14d9.htm) |
| CARGO Therapeutics, Inc. | $202M — computed | TD Cowen | $4.3M | 2.13% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1966494/000119312525163464/d78481dsc14d9.htm) |
| Sage Therapeutics, Inc. — acquired by Supernus Pharmaceuticals | $452M — computed | Goldman Sachs | $14.7M | 3.25% | [SC 14D9 Jul 2025](https://www.sec.gov/Archives/edgar/data/1597553/000119312525155020/d63256dsc14d9.htm) |
| Verve Therapeutics, Inc. — acquired by Eli Lilly and Company | $267M — computed | Centerview PartnersGuggenheim Securities | $33.7M | 12.60% | [SC 14D9 Jun 2025](https://www.sec.gov/Archives/edgar/data/1840574/000119312525146127/d917975dsc14d9.htm) |
| PHX Minerals Inc. — acquired by WhiteHawk Energy | $162M — computed | RBCCMIntrepid | $4.25M | 2.62% | [SC 14D9 May 2025](https://www.sec.gov/Archives/edgar/data/315131/000110465925051830/tm2515778-1_sc14d9.htm) |
| Checkpoint Therapeutics, Inc. — acquired by Sun Pharmaceutical Industries (LW Securities engaged) | $475M — computed | Kroll | $400K | 0.08% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1651407/000110465925038082/tm252489-4_defm14a.htm) |
| Akoya Biosciences, Inc. — acquired by Quanterix Corporation | $199M — computed | Perella Weinberg Partners | $3.5M | 1.76% | [DEFM14A Apr 2025](https://www.sec.gov/Archives/edgar/data/1711933/000110465925035134/tm2510802-1_defm14a.htm) |
| 2seventy bio, Inc. — acquired by Bristol-Myers Squibb | $262M — computed | Goldman Sachs | $8.58M | 3.28% | [SC 14D9 Apr 2025](https://www.sec.gov/Archives/edgar/data/1860782/000114036125013644/ny20046860x1_sc14d9.htm) |
| Logility Supply Chain Solutions, Inc — acquired by Aptean | $478M — computed | Lazard | $9.8M | 2.05% | [DEFM14A Mar 2025](https://www.sec.gov/Archives/edgar/data/713425/000114036125006872/ny20042527x2_defm14a.htm) |
| Poseida Therapeutics, Inc. | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524286056/d871087dsc14d9a.htm) |
| Poseida Therapeutics, Inc. — acquired by Roche | $390M — computed | Centerview Partners | $25.5M | 6.54% | [SC 14D9 Dec 2024](https://www.sec.gov/Archives/edgar/data/1661460/000119312524273550/d901928dsc14d9.htm) |
| Universal Stainless & Alloy Products Inc | $456M — stated | TD Cowen | $8.1M | 1.78% | [DEFM14A Nov 2024](https://www.sec.gov/Archives/edgar/data/931584/000119312524267249/d842335ddefm14a.htm) |
| ARC Document Solutions, Inc. | $162M — stated | William Blair | $1M | 0.62% | [DEFM14A Oct 2024](https://www.sec.gov/Archives/edgar/data/1305168/000114036124043469/ny20035563x8_defm14a.htm) |
| Iteris, Inc. — acquired by Almaviva | $308M — computed | Morgan Stanley | $10.5M | 3.41% | [DEFM14A Sep 2024](https://www.sec.gov/Archives/edgar/data/350868/000114036124041589/ny20034699x2_defm14a.htm) |
| G1 Therapeutics, Inc. | $259M — computed | Centerview PartnersGuggenheim Securities | $16.9M | 6.54% | [SC 14D9 Aug 2024](https://www.sec.gov/Archives/edgar/data/1560241/000119312524203615/d856692dsc14d9.htm) |
| Desktop Metal, Inc. | $349M — computed | Stifel | $4.2M | 1.20% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1754820/000110465924089909/tm2420443-3_defm14a.htm) |
| The Aaron's Company, Inc. — acquired by Iqv | $310M — computed | J.P. Morgan | $10.1M | 3.26% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1821393/000119312524199465/d816734ddefm14a.htm) |
| Alimera Sciences, Inc. | $498M — computed | Perella Weinberg PartnersCenterview Partners | $18M | 3.62% | [DEFM14A Aug 2024](https://www.sec.gov/Archives/edgar/data/1267602/000110465924087307/tm2419772-3_defm14a.htm) |
| SilverBow Resources, Inc. — acquired by Crescent | $391M — computed | BofA SecuritiesEvercore | $32M | 8.18% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/351817/000162828024030396/silverbow-defm14a.htm) |
| Whole Earth Brands, Inc. — acquired by Sababa | $211M — computed | JefferiesCiti | $13M | 6.17% | [DEFM14A Jun 2024](https://www.sec.gov/Archives/edgar/data/1753706/000114036124031141/ny20024121x13_defm14a.htm) |
| Transphorm, Inc. — acquired by Renesas | $323M — computed | BofA Securities | $6.21M | 1.92% | [DEFM14A Mar 2024](https://www.sec.gov/Archives/edgar/data/1715768/000119312524058005/d585789ddefm14a.htm) |

Showing 40 of 58, most recent first. The full list is on the dataset page.

## Los conjuntos de datos

- [660Honorarios de asesores de M&ADocumentos de fusión y ofertas públicas, 2023–2026. Honorarios por tamaño de operación, nivel de firma, sector y cliente, la parte pagadera al cierre y una ficha de cada banco frecuente.](https://dealcostindex.com/ma-advisor-fees-es.html)

- [288Honorarios legalesDespachos en salidas a bolsa, fusiones y procedimientos del Chapter 11: gastos legales de la salida a bolsa, tarifas horarias de socios y una ficha de cada despacho frecuente.](https://dealcostindex.com/legal-fees-es.html)

- [86Honorarios contablesAuditores de las salidas a bolsa en EE. UU. y los gastos contables que detallan los emisores, precios de las revisiones de calidad de resultados y una ficha de cada firma de auditoría frecuente.](https://dealcostindex.com/accounting-fees-es.html)

- [502Costes de salida a bolsaFolletos definitivos. Comisión de colocación y gastos legales, contables, de impresión y de admisión, detallados.](https://dealcostindex.com/ipo-costs-es.html)

- [52,571Comisiones de colocaciónRondas privadas declaradas en Form D, de 2023 Q1 a 2026 Q3. Comisiones y honorarios de intermediación por tamaño, valor y sector.](https://dealcostindex.com/capital-raise-fees-es.html)

- [47Retribuciones en el Chapter 11Expedientes judiciales. Honorarios mensuales, honorarios de reestructuración y tarifas horarias de los profesionales del deudor.](https://dealcostindex.com/restructuring-fees-es.html)

- [132Due diligence, seguro y depósitoEncuestas publicadas y tarifas de firmas para los costes que los registros no revelan operación por operación.](https://dealcostindex.com/diligence-insurance-es.html)

- [25Salas de datosPrecios de lista, estimaciones de terceros y certificaciones declaradas, calculados para su sala.](https://dealcostindex.com/vdr-es.html)

- [639Directorio de asesoresBancos, despachos y auditores procedentes de 27 listas públicas, la base de cada nivel de la calculadora.](https://dealcostindex.com/providers-es.html)

## Cómo citar el índice

Cite la página utilizada como Deal Cost Index, «<título de la página>», versión de datos 2026.10.3, con enlace. Los datos subyacentes están bajo licencia [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) y pueden descargarse en CSV desde la [página de metodología](https://dealcostindex.com/methodology-es.html); cada fila conserva el enlace al registro o a la publicación de la que procede.

Deal Cost Index. Data: CC BY 4.0.